Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose The estimated prevalence of migraines in South Korea is 6.0%, with affected patients having unmet needs. The efficacy, safety, and tolerability of galcanezumab, a humanized monoclonal antibody, for episodic migraine (EM) prevention was evaluated in South Korean patients. Methods During the double-blind period of the EVOLVE-2 phase 3 trial, patients with EM were randomized into placebo, 120 mg-galcanezumab, and 240-mg galcanezumab treatment groups. The primary endpoint was the overall mean change from baseline in the number of monthly migraine headache days during the 6-month double-blind period. We conducted a post-hoc analysis of the South Korean cohort in EVOLVE-2. Results Among 98 South Korean patients in the intent-to-treat population, significant changes from baseline were observed in the number of monthly migraine headache days in the 240- mg galcanezumab group compared with the placebo group (-2.64, p=0.013), in the percentage of patients with ≥50% reduction in the number of monthly migraine headache days (120 mg: odds ratio=2.43, p=0.030; 240 mg: odds ratio=2.60, p=0.019), in the number of monthly migraine headache days with acute medication use (120 mg: -2.22, p=0.006; 240 mg: -2.23, p=0.005), and in the Migraine-Specific Quality-of-Life Role Function-Restrictive (120 mg: 8.34, p=0.040). Numerical improvements from baseline were observed relative to the placebo group in at least one galcanezumab group for: the percentage of patients with ≥75% reduction in the number of monthly migraine headache days functional impairment, and disease severity. The most common treatment-emergent adverse event in the combined galcanezumab group was injection site reaction, which led to treatment discontinuation for one patient. Conclusions Galcanezumab treatment demonstrated efficacy and a favorable safety and tolerability profile in South Korean patients with EM.
Abstract
Background and Purpose The estimated prevalence of migraines in South Korea is 6.0%, with affected patients having unmet needs. The efficacy, safety, and tolerability of galcanezumab, a humanized monoclonal antibody, for episodic migraine (EM) prevention was evaluated in South Korean patients. Methods During the double-blind period of the EVOLVE-2 phase 3 trial, patients with EM were randomized into placebo, 120 mg-galcanezumab, and 240-mg galcanezumab treatment groups. The primary endpoint was the overall mean change from baseline in the number of monthly migraine headache days during the 6-month double-blind period. We conducted a post-hoc analysis of the South Korean cohort in EVOLVE-2. Results Among 98 South Korean patients in the intent-to-treat population, significant changes from baseline were observed in the number of monthly migraine headache days in the 240- mg galcanezumab group compared with the placebo group (-2.64, p=0.013), in the percentage of patients with ≥50% reduction in the number of monthly migraine headache days (120 mg: odds ratio=2.43, p=0.030; 240 mg: odds ratio=2.60, p=0.019), in the number of monthly migraine headache days with acute medication use (120 mg: -2.22, p=0.006; 240 mg: -2.23, p=0.005), and in the Migraine-Specific Quality-of-Life Role Function-Restrictive (120 mg: 8.34, p=0.040). Numerical improvements from baseline were observed relative to the placebo group in at least one galcanezumab group for: the percentage of patients with ≥75% reduction in the number of monthly migraine headache days functional impairment, and disease severity. The most common treatment-emergent adverse event in the combined galcanezumab group was injection site reaction, which led to treatment discontinuation for one patient. Conclusions Galcanezumab treatment demonstrated efficacy and a favorable safety and tolerability profile in South Korean patients with EM.
참고문헌 (42)
- Woldeamanuel YW, "Migraine affects 1 in 10 people worldwide featuring recent rise : a systematic review and meta-analysis of community-based studies involving 6 million participants", J Neurol Sci, 372, pp.307~315 (2017)
- Peng KP, "Epidemiology of headache disorders in the Asiapacific region", Headache, 54, pp.610~618 (2014)
- Song TJ, "Sex differences in prevalence, symptoms, impact, and psychiatric comorbidities in migraine and probable migraine : a population-based study", Headache, 59, pp.215~223 (2019)
- Chu MK, "Gender-specific influence of socioeconomic status on the prevalence of migraine and tension-type headache : the results from the Korean headache survey", J Headache Pain, 14, pp.82~ (2013)
- 김병건, "Prevalence and Impact of Migraine and Tension-Type Headache in Korea", Journal of Clinical Neurology, 8(3), pp.204~211 (2012), 대한신경과학회[DOI]
- Kim BK, "Prevalence, clinical characteristics and disability of migraine and probable migraine : a nationwide population-based survey in Korea", Cephalalgia, 33, pp.1106~1116 (2013)
- 김경민, "Prevalence, Disability, and Management Patterns of Migraine in Korea: Nationwide Survey Data from 2009 and 2018", Journal of Clinical Neurology, 17(1), pp.77~85 (2021), 대한신경과학회
- Leonardi M, "A narrative review on the burden of migraine : when the burden is the impact on people’s life", J Headache Pain, 20, pp.41~ (2019)
- Adams AM, "The impact of chronic migraine : the chronic migraine epidemiology and outcomes(CaMEO)study methods and baseline results", Cephalalgia, 35, pp.563~578 (2015)
- Lipton RB, "A comparison of the chronic migraine epidemiology and outcomes(CaMEO)study and American migraine prevalence and prevention(AMPP)study : demographics and headache-related disability", Headache, 56, pp.1280~1289 (2016)
- Buse DC, "Life with migraine : effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes(CaMEO)study", Headache, 59, pp.1286~1299 (2019)
- Silberstein SD, "Preventive migraine treatment", Continuum(Minneap Minn), 21, pp.973~989 (2015)
- 김병건, "Prevalence Rates of Primary Headache Disorders and Evaluation and Treatment Patterns Among Korean Neurologists", Journal of Clinical Neurology, 18(5), pp.571~580 (2022), 대한신경과학회
- 문희수, "편두통 치료의 최신 지견", 대한신경과학회지, 38(2), pp.100~110 (2020), 대한신경과학회
- Blumenfeld AM, "Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine : results from the second international burden of migraine study(IBMS-II)", Headache, 53, pp.644~655 (2013)
- Berger A, "Adherence with migraine prophylaxis in clinical practice", Pain Pract, 12, pp.541~549 (2012)
- Rau JC, "Other preventive anti-migraine treatments : ACE inhibitors, ARBs, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists", Curr Treat Options Neurol, 21, pp.17~ (2019)
- Durham PL, "Calcitonin gene-related peptide(CGRP)and migraine", Headache, 46(Suppl 1), pp.S3~S8 (2006)
- Ho TW, "CGRP and its receptors provide new insights into migraine pathophysiology", Nat Rev Neurol, 6, pp.573~582 (2010)
- Lassen LH, "CGRP may play a causative role in migraine", Cephalalgia, 22, pp.54~61 (2002)
- Chiang CC, "Calcitonin gene-related peptide(CGRP)-targeted therapies as preventive and acute treatments for migrainethe monoclonal antibodies and gepants", Prog Brain Res, 255, pp.143~170 (2020)
- Stauffer VL, "Evaluation of galcanezumab for the prevention of episodic migraine : the EVOLVE-1 randomized clinical trial", JAMA Neurol, 75, pp.1080~1088 (2018)
- Skljarevski V, "Efficacy and safety of galcanezumab for the prevention of episodic migraine : results of the EVOLVE-2 phase 3 randomized controlled clinical trial", Cephalalgia, 38, pp.1442~1454 (2018)
- Sakai F, "Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine : a phase 2 randomized controlled clinical trial", Cephalalgia Rep, 3, pp.2515816320932573~ (2020)
- Detke HC, "Galcanezumab in chronic migraine : the randomized, double-blind, placebo-controlled REGAIN study", Neurology, 91, pp.e2211~e2221 (2018)
- Mulleners WM, "Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed(CONQUER) : a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial", Lancet Neurol, 19, pp.814~825 (2020)
- Reuter U, "Galcanezumab in patients with multiple previous migraine preventive medication category failures : results from the open-label period of the CONQUER trial", Adv Ther, 38, pp.5465~5483 (2021)
- Hirata K, "A long-term open-label safety study of galcanezumab in Japanese patients with migraine", Expert Opin Drug Saf, 20, pp.721~733 (2021)
- Detke H, "One-year treatment with galcanezumab in patients with chronic migraine : results from the open-label phase of the REGAIN study", Neurology, 92(15 Supplement), pp.P2.10-010~ (2019)
- Camporeale A, "A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine", BMC Neurol, 18, pp.188~ (2018)
- Lamb YN, "Galcanezumab : first global approval", Drugs, 78, pp.1769~1775 (2018)
- "Drugs@FDA: FDA-approved drugs"[URL]
- "Emgality" (2022)[URL]
- "Lilly’s migraine treatment Emgality lands in Korea" (2019)[URL]
- Martin BC, "Validity and reliability of the migraine-specific quality of life questionnaire(MSQ version 2. 1)", Headache, 40, pp.204~215 (2000)
- Seo JG, "Validation of the Korean migraine-specific quality of life questionnaire version 2. 1 in episodic and chronic migraine", J Oral Facial Pain Headache, 31, pp.251~256 (2017)
- Bagley CL, "Validating migraine-specific quality of life questionnaire v2. 1 in episodic and chronic migraine", Headache, 52, pp.409~421 (2012)
- Stewart WF, "Development and testing of the migraine disability assessment(MIDAS)questionnaire to assess headache-related disability", Neurology, 56(6 Suppl 1), pp.S20~S28 (2001)
- Lee HS, "The reliability and validity of the MIDAS(migraine disability assessment)questionnaire for Korean migraine sufferers", J Korean Neurol Assoc, 18, pp.287~291 (2000)
- Evers S, "Clinical features, pathophysiology, and treatment of medication-overuse headache", Lancet Neurol, 9, pp.391~401 (2010)
- Wang SJ, "Migraine disability awareness campaign in Asia : migraine assessment for prophylaxis", Headache, 48, pp.1356~1365 (2008)
- Kim BK, "Correction to : burden of migraine and unmet needs from the patients’ perspective : a survey across 11 specialized headache clinics in Korea", J Headache Pain, 22, pp.56~ (2021)